Why the study?
Does sparfloxacin cause clinically significant QTc prolongation or adverse cardiovascular events?
Population
Dogs, healthy volunteers, and patients including those with renal or hepatic impairment and underlying…
Design
Review
Authors
Loading...
May warrant QTc caution in patients with cardiac disease; leaves open arrhythmic risk of moderate prolongation in others.
Does sparfloxacin cause clinically significant QTc prolongation or adverse cardiovascular events?
Sparfloxacin causes a moderate (3%) prolongation of the QTc interval, but serious cardiovascular events are rare and appear limited to patients with pre-existing cardiac conditions.
Jaillon et al. (1996) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: